our team

Everyone at AMF Medical is keen to see medical technology make a difference.  Discover what motivates everyone in this highly skilled and experienced team: a passion for user-centric design combined with innovative microfluidics engineering toward better treatment options. 

We know that Sigi™ will be an integral part of our customers’ life: every day, 24/7, year in-year out.  This is why, besides safety and security first and foremost, we never settle for less than the best possible ease-of-use in all we do, and perhaps why Sigi™ has been referred to as ‘the Nespresso of insulin patch pumps’. 


“We are passionate about creating the best technology and product to help people with diabetes.”

Antoine Barraud, PhD

Co-CEO and Co-founder

Antoine brings to AMF Medical 18 years experience in the Life Sciences, Space and Watch industries. Specialized in product development and industrialization, he worked during his PhD at EPFL on an insulin micropump and an implantable glucose sensor, which were further developed at Sensile Medical. Antoine holds a Master’s degree in Physics and PhD in Biosensing from EPFL.

“Sigi™ will be the first insulin patch pump without compromises – just simple and easy, the way people with diabetes want it to be.”

Pim van Wesel


Pim is an international MedTech executive, specializing in commercialization and general management for almost 20 years. During his 5-year tenure at Medtronic Diabetes, he developed a strong know-how of the insulin pump market and built a global network among key stakeholders. Prior to earning his MBA from IMD, he worked at ING Corporate Banking. He also holds a Master’s degree in Applied Economics.

“Sigi™ wants its technology to be so easy you can almost forget about it. We are thinking everything through, down to the smallest design details, to make Sigi™ fit simply into the life of people with diabetes.”

Pierre Fridez, PhD

Product Development Director

Pierre has been conceiving and creating Medical Devices for more than 20 years working across all development stages, interweaving his profound engineering expertise with regulatory and clinical research know-how. Highlights of his career include his instrumental role in the success of EndoArt, an EPFL startup sold to Allergan for CHF 120 M, and in the development of EMS’ dental prophylaxis devices which remain commercially successful. He holds a Master’s degree in Physics and a PhD in Biomechanics from EPFL.

“Peace of mind for users of Sigi™ comes from its Swiss quality, reliability, and safety – we pursue these values every day, relentlessly!”

Alain Woodtli

QA/RA Director

Alain has been leading device design, regulatory affairs, and quality teams in MedTech for over 25 years and brings vast experience in Quality Assurance (ISO 13485) and Regulatory Approvals of Medical Devices (CE-marking, FDA) to the development process of Sigi™ . Alain holds a Master’s degree in Physics from the University of Neuchâtel.

“The Sigi™ insulin pump is an breakthrough device that will help improve the daily lives of the many people with diabetes.”

Markus Kohli, PhD

Industrialization and Production Director

Markus brings to AMF Medical over 20 years experience in product industrialization projects. He co-founded a start-up and led the industrialization of laser-based gas sensors & micro machined infrared detectors. He also spent a decade at Nestlé leading the industrialization of an innovative infant formula beverage capsule. Markus holds a Master’s degree in Physics from ETHZ and PhD in Material Science from EPFL.

Board Members

“Making a difference for people with diabetes is what drives the AMF Medical team – this is why they will succeed!”

Prof. Dr. Peter Ryser

Chairman and Co-founder

Peter Ryser is a co-founder of Sensile Technologies, and was a Professor of Microengineering at the Swiss Federal Institute of Technology in Lausanne for 16 years. Peter holds a PhD. in Applied Physics from the University of Geneva, a Master’s degree in Experimental Physics and an MBA from the University of Applied Sciences in Lucerne. He is also a member of the Swiss Academy of Engineering Sciences.

“Investing in better medicine is an honor and privilege. I look forward to seeing Sigi™ putting a smile on the face of many people with diabetes!”

Ronald Strässler

Investor, Board Member

Ronald Strässler is co-founder of Avaloq Group and architect of the Avaloq Core Banking Suite. Avaloq is a Switzerland-based global leader in digital banking solutions, core banking software and wealth management technology, sold in 2020 for CHF 2 billion to NEC Corporation, a leading Japanese IT group.

For me, Sigi™ stands for simplicity – I am keen to see People with Diabetes benefiting from its secure and safe ease-of-use.

Peter Gerhardsson

Board Member

Peter Gerhardsson has extensive experience with diabetes therapies. From 1980 to 2000, he held various roles at Novo Nordisk. In 2000, he joined MiniMed, which Medtronic acquired in 2001 and where he continued to lead its European diabetes business. Subsequently, he joined Dexcom as Vice President International Business Development, from 2008 till his retirement in 2018. Thereafter, he joined Institute for Applied Economics and Health Research in Copenhagen as Partner.

Sigi™ should significantly expand the number of people using an insulin patch pump due to the company’s focus in making a product small, accurate and simple-to-use.

John Timberlake

Board Member

John Timberlake has 30+ years of healthcare executive leadership with an accomplished track‐record commercializing diabetes medical devices, drugs, and drug‐device combinations. John is currently CEO of Berkshire Biomedical Corporation, and was previously CEO and Board Member of Valeritas, the original maker of V-Go®, as well as VP at Sanofi, responsible for their U.S. diabetes portfolio, including Lantus®. He earned a Master’s degree in Management from Purdue University, and an MBA from ESC Rouen, France (now NEOMA Business School).


“Sigi™ will be a brilliant addition to the treatment options for people with Type I diabetes – adults and children – because of its extremely effective micro-dosing.”

Barry Wilson

Barry Wilson is a global healthcare executive. He retired as President International with Medtronic Inc, the world’s largest MedTech company. Previously, he served as President of Lederle International (acquired by Pfizer), President of Europe and Intercontinental for Bristol Myers Squibb, and he had 8 international assignments with Pfizer Inc. Barry has an MBA from the Wharton School and an MA from Cambridge University.

“Sigi™ has the potential to become a Swiss start-up success: a bold vision, a world-class engineering and management team, and a supportive ecosystem.”


Katrin Siebenbürger Hacki has over 15 years’ experience in the Medical Device industry where she gained broad expertise in market development, sales force excellence and sales & marketing execution. She is specialized in using healthcare system data to guide product development, go-to-market, international expansion and innovative pricing models for medical technology and diagnostics manufacturers. Katrin holds a MSc in Biotechnology from the École Supérieure de Biotechnologie de Strasbourg (ESBS) and an MBA from IMD in Lausanne.

“Sigi’s features and benefits will resonate well with future users: it’s one of these innovations that meet a clear need, and the AMF team has what it takes to make it happen.”

Dr. med. David Stocker

David supports AMF Medical with over a decade of international experience in diabetes technology, and a strong personal network among experts and other key stakeholders. David has built and scaled up a number of highly successful MedTech start-ups after working as a physician at Zurich University hospital, from which he holds an MD Degree. He advises AMF Medical on matters related to medical affairs, regulatory approvals, market access, and marketing communication.

“The Sigi™ pump represents the next generation of insulin pumps, applying the latest technology to deliver a simple pump with no compromises on accuracy, reliability, and user-friendliness.”

Doug Lawrence

Doug Lawrence brings 30 years of medical device expertise to AMF Medical, including extensive diabetes know-how acquired as global Vice President of Becton Dickinson’s Insulin Injection business. He holds a Systems Engineering degree from the University of Pennsylvania, and business degrees from the University of Pennsylvania’s Wharton School and Northwestern University’s Kellogg School.

If you want to join us, partner with us, or invest in us

let’s collaborate